Polivy (Polatuzumab Vedotin) is a targeted therapy that combines an anti-CD79b monoclonal antibody with a cytotoxic agent, selectively delivering chemotherapy to B-cell lymphoma cells. It is primarily indicated for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in combination with other anticancer agents.
Key Features:
Active Ingredient: Polatuzumab Vedotin
Strength: 140mg
Form: Powder for concentrate for solution for infusion
Manufacturer: Roche
Indications:
Polivy is commonly prescribed for the treatment of:
- Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
- Used in combination with bendamustine and rituximab
Administration and Dosage:
Administered via intravenous infusion under medical supervision. The dosage and treatment schedule depend on the patient’s condition and response to therapy. Premedication with antihistamines and corticosteroids may be recommended to minimize infusion-related reactions.
Storage Instructions:
Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light and keep in the original packaging.
Precautions:
Monitor for peripheral neuropathy, myelosuppression, and infusion-related reactions. Patients should be closely observed for progressive multifocal leukoencephalopathy (PML). Not recommended during pregnancy or breastfeeding.
Note: This is a prescription-only medication and should be used under the guidance of a healthcare professional.
Reviews
There are no reviews yet.